Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 7, 2012, Pages 778-784

  Sipponen, Taina ^a   Haapamäki, Johanna ^a   Savilahti, Erkki ^b   Alfthan, Henrik ^a   Hämäläinen, Esa ^a   Rautiainen, Henna ^c   Koskenpato, Jari ^a   Nuutinen, Hannu ^a   Färkkilä, Martti ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Foundation for Paediatric Research   (Finland)

^c JORVI HOSPITAL   (Finland)

Author keywords

biomarkers; Crohn's disease activity; fecal markers; IBD; small intestine

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CALGRANULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN S 100; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAPSULE ENDOSCOPE; CAPSULE ENDOSCOPY; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENTEROPATHY; ESOPHAGOGASTRODUODENOSCOPY; FECES LEVEL; FEMALE; HUMAN; ILEOCOLONOSCOPY; INTESTINE ISCHEMIA; INTESTINE POLYP; INTESTINE TUMOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE;

ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CAPSULE ENDOSCOPY; CROHN DISEASE; FECES; FEMALE; HUMANS; INTESTINE, SMALL; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; S100 PROTEINS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84862225299     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.677953     Document Type: Article

References (28)

1. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease. Definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
2. Gralnek IM, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis B. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008;27:146-54. (Pubitemid 350256605)
3. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60. (Pubitemid 34827189)
4. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80. (Pubitemid 27163169)
5. Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, et al. Faecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13. (Pubitemid 350206297)
6. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6. (Pubitemid 351196867)
7. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20. (Pubitemid 39388470)
8. Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, Turunen U, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-8.
9. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-21. (Pubitemid 39279049)
10. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, inpatients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4. (Pubitemid 29074787)
11. Aggarwal V, Day AS, Connor SJ, Leach ST, Grimm MC, Craig PI. Capsule endoscopy findings in small bowel Crohn's disease patients in clinical remission. Correlation with the Crohn's disease Activity Index, faecal calprotectin and S100A12. Gastroenterology 2010;138(5 Suppl 1):S-114.
12. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
13. Mow WS, Lo SK, Targan SR, Dubinsky MC, Treyzon L, Abreu-Martin MT, et al. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:31-40. (Pubitemid 38165397)
14. Tibble J, TeahonK, ThjodleifssonB,RosethA, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
15. Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 2007;42:1321-31. (Pubitemid 47537067)
16. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8. (Pubitemid 40299092)
17. D'Inca R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14.
18. Garcia Sanchez V, Iglesias Flores E, Gonzalez R, Gisbert JP, Gallardo-Valverde JM, Gonzalez-Galilea A, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis. J Crohns Colitis 2010;4:144-52.
19. Koulaouzidis A, Douglas S, Arnott I, Plevris JN. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol 2011;46:561-6.
20. Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9.
21. Schroder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-42. (Pubitemid 47416301)
22. Bourreille A, Ignjatovic A, Aabakken L, Loftus EV Jr, Eliakim R, Pennazio M, et al. World Organisation of Digestive Endoscopy (OMED) and the European Crohn's and Colitis Organisation (ECCO). Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009;41:618-37.
23. Fidder HH, Nadler M, Lahat A, Lahav M, Bardan E, Avidan B, et al. The utility of capsule endoscopy in the diagnosis of Crohn's disease based on patient's symptoms. J Clin Gastroenterol 2007;41:384-7. (Pubitemid 46573067)
24. Montalto M, Curigliano V, Santoro L, Lombarda M, Covino M, Cammarota G, et al. Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. Eur J Gastroenterol Hepatol 2006;18:965-7. (Pubitemid 44213039)
25. Smecuol E, Pinto Sanchez MI, Suarez A, Argonz JE, Sugai E, Vazquez H, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009;7:524-9.
26. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6. (Pubitemid 29400711)
27. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007;25:1211-22. (Pubitemid 46650300)
28. Montalto M, Gallo A, Ianiro G, Santero L, D'Onofrio F, Ricci R, et al. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol 2010;16:3406-10.